Bookmark Article
Pfizer’s stock hit a new 52-week low but recovered to close higher following global uncertainty caused by the tariff war and fears of a global recession. Despite a decline in COVID revenues, Pfizer’s non-COVID operational revenues improved in 2024, driven by key products in oncology. The company faces challenges such as declining COVID product sales and upcoming patent expirations, but remains attractive from a valuation standpoint and is making a comeback with a strong performance in 2024.
Full Article
